Delayed post-hypoxic leukoencephalopathy (DHPL) is a demyelinating syndrome characterized by acute onset of neuropsychiatric symptoms within days to weeks following apparent recovery from coma after a period of prolonged cerebral hypo-oxygenation. The majority of DPHL cases are associated with carbon monoxide intoxication. There is no specific treatment, and the prognosis is usually poor. However, we present a case of DHPL patient with akinetic mutism, parkinsonism, stool and urine incontinence, and severe cognitive impairment improved after treatment with high-dose steroid therapy.

Mild cognitive impairment (MCI) is an intermediate cognitive state between normal aging and dementia. It has disparate features in activities of daily life which is interfered notably in dementia. Recently, there have been consistent reports of MCI which is predementia, however significant controversy exist. In this review, we make out the diagnostic criteria, classification, risk factor, prevalence, diagnostic test including neuroimaging and biomarkers, management, and prognosis of MCI. This review will cover current knowledge and future directions on MCI.
Aging ; Biomarkers ; Classification ; Dementia ; Diagnostic Tests, Routine ; Mild Cognitive Impairment* ; Neuroimaging ; Prevalence ; Prognosis ; Risk Factors

Background: and Purpose The wearing-off (WO) phenomenon is the most common motor complication in advanced Parkinson’s disease (PD), but its identification remains challenging. The 9- and 19-item Wearing-off Questionnaires (WOQ-9 and WOQ-19) are self-assessment tools for motor and nonmotor symptoms that are widely used for WO screening. We produced Korean versions of the WOQ-19 and WOQ-9 (K-WOQ-19 and K-WOQ-9) and investigated their validity and reliability. Methods: We used the translation–back translation method to produce K-WOQ-19 and KWOQ-9, which were self-administered by 124 patients with PD. We conducted in-depth 10-minute interviews for confirming the presence of the WO phenomenon, and then stratified the participants into groups with and without WO. Diagnostic accuracy was assessed by analyzing receiver operating characteristic curves. Concurrent validity was assessed using the Movement Disorder Society–Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) and the Hoehn and Yahr stage with Spearman’s rank correlation analysis. Reliability was assessed based on test–retest Cohen’s kappa (κ) values and intraclass correlation coefficients (ICCs). Results: The optimal cutoff scores on the K-WOQ-19 and K-WOQ-9 for WO screening were 4 and 2, respectively. The test–retest ICCs of K-WOQ-19 and K-WOQ-9 were 0.943 and 0.938, respectively. Nineteen of the combined 20 items in K-WOQ-19 and K-WOQ-9 showed moderate-to-substantial agreement (κ=0.412–0.771, p<0.001). The scores on the translated scales were significantly correlated with MDS-UPDRS IV scores. Conclusions K-WOQ-19 and K-WOQ-9 are reliable and valid tools for detecting WO, with optimal cutoff scores of 4 and 2, respectively.

Hemichorea after cortical infarction has rarely been reported. We report a female patient in which hemichorea of the right extremities developed following a left temporo-parietal infarction. An acute infarction in the territory of the inferior division of the left middle cerebral artery was evident in diffusion-weighted imaging, but the basal ganglia, thalamus, and brainstem appeared normal. Her choreic movement gradually improved after administering haloperidol, and the hemichorea disappeared after 4 days.
Basal Ganglia ; Brain Stem ; Chorea ; Extremities ; Female ; Haloperidol ; Humans ; Infarction* ; Middle Cerebral Artery ; Thalamus

Sleep disorders are common, occurring in both healthy elderly people and in association with neurodegenerative diseases, sometimes preceding other clinical manifestations of those diseases. The sleep disorders of neurodegenerative diseases include insomnia, hypersomnia, parasomnia, excessive nocturnal motor activity, circadian sleep-wake rhythm disturbances, and sleep breathing disorders. This review addresses the neuroanatomical basis of sleep, the associated regulatory mechanisms and neurotransmitters, and the relationship between cognitive function and sleep. Furthermore, the clinical features of sleep disorders in a wide variety of neurodegenerative diseases are reviewed, including movement disorders and dementia.
Aged ; Dementia* ; Disorders of Excessive Somnolence ; Humans ; Motor Activity ; Movement Disorders* ; Neurodegenerative Diseases ; Neurotransmitter Agents ; Parasomnias ; Respiration ; Sleep Wake Disorders* ; Sleep Initiation and Maintenance Disorders

BACKGROUND AND PURPOSE: Repetitive transcranial magnetic stimulation (rTMS) has been examined as a potential treatment for many neurological disorders. High-frequency rTMS in particular improves cognitive functions such as verbal fluency and memory. This study explored the effect of rTMS combined with cognitive training (rTMS-COG) on patients with Alzheimer's disease (AD). METHODS: A prospective, randomized, double-blind, placebo-controlled study was performed with 27 AD patients (18 and 8 in the treatment and sham groups, respectively, and 1 drop-out). The participants were categorized into mild [Mini-Mental State Examination (MMSE) score=21-26] and moderate (MMSE score=18-20) AD groups. The rTMS protocols were configured for six cortical areas (both dorsolateral prefrontal and parietal somatosensory associated cortices and Broca's and Wernicke's areas; 10 Hz, 90-110% intensity, and 5 days/week for 6 weeks). Neuropsychological assessments were performed using the AD Assessment Scale-cognitive subscale (ADAS-cog), Clinical Global Impression of Change (CGIC), and MMSE before, immediately after, and 6 weeks after the end of rTMS-COG treatment. RESULTS: Data from 26 AD patients were analyzed in this study. There was no significant interactive effect of time between the groups. The ADAS-cog score in the treatment group was significantly improved compared to the sham group (4.28 and 5.39 in the treatment group vs. 1.75 and 2.88 in the sham group at immediately and 6 weeks after treatment, respectively). The MMSE and CGIC scores were also improved in the treatment group. Based on subgroup analysis, the effect of rTMS-COG was superior for the mild group compared to the total patients, especially in the domains of memory and language. CONCLUSIONS: The present results suggest that rTMS-COG represents a useful adjuvant therapy with cholinesterase inhibitors, particularly during the mild stage of AD. The effect of rTMS-COG was remarkable in the memory and language domains, which are severely affected by AD.
Alzheimer Disease* ; Cholinesterase Inhibitors ; Cognitive Therapy ; Humans ; Memory ; Nervous System Diseases ; Prospective Studies* ; Rabeprazole ; Transcranial Magnetic Stimulation*